Introduction
Located at Switzerland Innovation Park Basel, Immuna Therapeutics combines world-class GMP manufacturing with innovative TricarT development. This strategic position enables seamless partnerships and accelerates cell & gene therapy advancement globally.
Collaboration Models for Clinical and Research Partners
- Academic Partnerships
- Joint research programs with universities and medical centers
- Technology transfer and shared IP development
- Access to specialized GMP facilities
- Clinical Partnerships
- Contract manufacturing for biotech companies
- Co-development agreements for novel therapeutics
- Licensing partnerships for market expansion
- Research Support
- Service agreements for vector supply
- Collaborative research arrangements
- Training and knowledge exchange programs
Ensuring Robustness and Reliability in GMP Vector Manufacturing
- Swiss Quality Standards
- EU-aligned GMP compliance and rigorous QA protocols
- Regular regulatory inspections and monitoring
- Full batch traceability and testing
- Operational Excellence
- State-of-the-art facilities at Innovation Park Basel
- Validated, scalable manufacturing processes
- 24/7 monitoring and redundant systems
- Expert technical teams ensuring consistency
Building a Pivotal Ecosystem for Cellular Immunotherapy
- Innovation Hub
- Continuous R&D in next-generation cell therapies
- Collaborative technology development with partners
- Access to cutting-edge platforms
- Talent & Knowledge
- Training programs for emerging biotech professionals
- Industry conferences and workshops
- Mentorship for startups and research teams
- Global Impact
- Accelerated therapy development and deployment
- Expanded patient access through cost-efficient pathways
- Sustainable ecosystem for long-term innovation
Conclusion
As a pivotal hub in Switzerland’s biotech landscape, Immuna transforms Basel into a launchpad for cell & gene therapy innovation—delivering reliable manufacturing, collaborative partnerships, and advancing cellular immunotherapy for patients worldwide.
